Lenacapavir: Patient and healthcare provider perceptions and the potential role for a twice-yearly injectable HIV treatment.
Alford K. et al, (2024), HIV Med
HBV001: Phase I study evaluating the safety and immunogenicity of the therapeutic vaccine ChAdOx1-HBV.
Cargill T. et al, (2023), JHEP reports : innovation in hepatology, 5
Re-valuation of annual cytology using HPV self-sampling to upgrade prevention (REACH UP): A feasibility study in women living with HIV in the UK.
Cicconi P. et al, (2022), HIV Med, 23, 390 - 396
Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002)
Flaxman A. et al, (2021), The Lancet, 398, 981 - 990
Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial
Ramasamy MN. et al, (2020), The Lancet, 396, 1979 - 1993
Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial
Folegatti PM. et al, (2020), The Lancet, 396, 467 - 478
MHC class II invariant chain-adjuvanted viral vectored vaccines enhances T cell responses in humans.
Esposito I. et al, (2020), Science translational medicine, 12
First-in-Human Randomized Study to Assess the Safety and Immunogenicity of an Investigational Respiratory Syncytial Virus (RSV) Vaccine Based on Chimpanzee-Adenovirus-155 Viral Vector-Expressing RSV Fusion, Nucleocapsid, and Antitermination Viral Proteins in Healthy Adults.
Cicconi P. et al, (2020), Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 70, 2073 - 2081
Evolution of transmitted HIV-1 drug resistance and viral subtypes circulation in Italy from 2006 to 2016
Rossetti B. et al, (2018), HIV Medicine, 19, 619 - 628
A Novel Vaccine Strategy Employing Serologically Different Chimpanzee Adenoviral Vectors for the Prevention of HIV-1 and HCV Coinfection.
Hartnell F. et al, (2018), Frontiers in immunology, 9
Pathophysiology of ischaemic heart disease
Pocock MO. et al, (2017), Current Opinion in HIV and AIDS, 12, 548 - 553
Brief Report: Soluble CD163 in CMV-Infected and CMV-Uninfected Subjects on Virologically Suppressive Antiretroviral Therapy in the ICONA Cohort
Vita S. et al, (2017), JAIDS Journal of Acquired Immune Deficiency Syndromes, 74, 347 - 352
The role of baseline HIV-1 RNA, drug resistance, and regimen type as determinants of response to first-line antiretroviral therapy
Di Biagio A. et al, (2014), Journal of Medical Virology, 86, 1648 - 1655
Efficacy and Safety of Darunavir/Ritonavir Plus Etravirine Dual Regimen in Antiretroviral Therapy–Experienced Patients: A Multicenter Clinical Experience
Gazzola L. et al, (2014), HIV Clinical Trials, 15, 140 - 150
Darunavir-based dual therapy in HIV experienced patients.
Sterrantino G. et al, (2014), Journal of the International AIDS Society, 17
Duration of first-line antiretroviral therapy with tenofovir and emtricitabine combined with atazanavir/ritonavir, efavirenz or lopinavir/ritonavir in the Italian ARCA cohort
Di Biagio A. et al, (2013), Journal of Antimicrobial Chemotherapy, 68, 200 - 205
Inconsistent condom use among HIV-positive women in the “Treatment as Prevention Era”: data from the Italian DIDI study
Cicconi P. et al, (2013), Journal of the International AIDS Society, 16, 18591 - 18591
Induced first abortion rates before and after HIV diagnosis: results of an Italian self-administered questionnaire survey carried out in 585 women living with HIV
Ammassari A. et al, (2013), HIV Medicine, 14, 31 - 39
TB meningitis in HIV-positive patients in Europe and Argentina: clinical outcome and factors associated with mortality.
Efsen AMW. et al, (2013), BioMed research international, 2013
Prevalence of Prolonged Amenorrhea in HIV-Infected Women
Cicconi P. et al, (2012), JAIDS Journal of Acquired Immune Deficiency Syndromes, 61, e19 - e21